Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for ATNM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
March 31, 2026 42.13M
December 31, 2025 48.00M
September 30, 2025 53.39M
June 30, 2025 59.93M
March 31, 2025 65.32M
December 31, 2024 72.90M
September 30, 2024 78.66M
June 30, 2024 86.04M
March 31, 2024 84.06M
December 31, 2023 76.68M
September 30, 2023 82.98M
June 30, 2023 91.28M
March 31, 2023 94.92M
December 31, 2022 109.31M
September 30, 2022 112.21M
June 30, 2022 116.72M
March 31, 2022 72.41M
December 31, 2021 78.22M
September 30, 2021 82.08M
June 30, 2021 81.96M
March 31, 2021 72.30M
December 31, 2020 63.61M
September 30, 2020 48.28M
June 30, 2020 53.51M
March 31, 2020 5.99M
Date Value
December 31, 2019 9.302M
September 30, 2019 14.36M
June 30, 2019 19.61M
March 31, 2019 9.965M
December 31, 2018 13.71M
September 30, 2018 14.85M
June 30, 2018 21.51M
March 31, 2018 26.80M
December 31, 2017 17.40M
September 30, 2017 20.54M
June 30, 2017 11.46M
March 31, 2017 17.09M
December 31, 2016 20.55M
September 30, 2016 15.56M
June 30, 2016 20.49M
March 31, 2016 22.24M
December 31, 2015 25.68M
September 30, 2015 24.77M
June 30, 2015 25.97M
March 31, 2015 19.30M
December 31, 2014 6.707M
September 30, 2014 11.75M
June 30, 2014 14.67M
March 31, 2014 5.878M
December 31, 2013 5.533M

Cash and Short Term Investments Definition

Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 851.46M
Alnylam Pharmaceuticals, Inc. 3.009B
Anika Therapeutics, Inc. 41.02M
Savara, Inc. 202.77M
Vericel Corp. 145.34M